ArticleFrontiers in cardiovascular medicine2026
Ex situ heart perfusion: a novel model for drug validation and translation.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ex situ heart perfusion (ESHP) was first developed in the 19th century by the German physician Oskar Langendorff. In recent years, ESHP has been critical to the development of donation after circulatory determination of death (DCD) programmes around the globe. ESHP has potential uses that extend far beyond transplantation. Here, we argue that ESHP, and more broadly all ex situ organ perfusion, should be utilised to perform first-in-human studies using turned down donor hearts and explanted recipient hearts from transplantation. This model would enable significantly earlier testing of novel therapeutics in human hearts, with minimal risk to patients. Widespread adoption of this model could streamline drug discovery pipelines, by enabling inefficacious therapeutics to be abandoned earlier in the drug development process. This model is particularly attractive given the high proportion of medicines that fail in stage II and stage III clinical trials due to a lack of efficacy. Development of this model will be dependent on prolonging ex situ perfusion times. Collaboration between industry, academics and clinicians will be needed to ensure successful widespread adoption of this model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.